Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A
Phase of Trial: Phase III
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms PATHFINDER 3
- Sponsors Novo Nordisk
- 01 Feb 2018 This trial has been completed in Sweden.
- 22 Nov 2017 Planned number of patients changed from 43 to 49.
- 22 Nov 2017 Planned End Date changed from 1 Dec 2018 to 3 Dec 2018.